Clinical trials: Community-acquired Pneumonia
Community Acquired Bacterial Pneumonia
Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and efficacy of delafloxacin compared to moxifloxacin in the treatment of adult patients with community-acquired pneumonia.
- Trial name
- DEFINE-CABP (NCT02679573)
- Testing
- Delafloxacin, Moxifloxacin, Linezolid
- Where
- 90 sites in United States, Argentina and 16 more
- Volunteers
- 860 people
- Sponsor
- Melinta Therapeutics, Inc.
Community-acquired Pneumonia
Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
The purpose of this study is to evaluate the pharmacokinetics of an oral omadacycline dosing regimen in the treatment of adults with CABP.
- Trial name
- NCT04160260
- Testing
- Omadacycline
- Where
- 13 sites in United States
- Volunteers
- 18 people
- Sponsor
- Paratek Pharmaceuticals Inc
Pneumonia
Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride
The purpose of this study is to Evaluate the Efficacy, safety and pharmacokinetics of Intravenous Nemonoxacin Compared with Intravenous Moxifloxacin in Adult Patients with community-acquired pneumonia (CAP).
- Trial name
- NCT01944774
- Testing
- Nemonoxacin 500 mg, Nemonoxacin 650 mg, Moxifloxacin 400 mg
- Where
- 2 sites in China, Taiwan
- Volunteers
- 207 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Respiratory Tract Infections
Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine
To describe the relief of symptoms, tolerability, and compliance of treatment with Klacid® sustained release (SR) at a dose of 1000 mg once daily in patients with acute tracheitis, acute tracheobronchitis, acute bronchitis, or in…
- Trial name
- KLARAINE (NCT01095978)
- Testing
- Clarithromycin (Klacid SR)
- Where
- 126 sites in Ukraine
- Volunteers
- 2,822 people
- Sponsor
- Abbott
Community Acquired Pneumonia
Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
The aim of this study is to test if BPS (Bacterial Pneumonia Score) guided antibiotic use in children with non severe community acquired pneumonia (CAP) and pneumoccocal vaccine will reduce antibiotic use as compared to standard…
- Trial name
- NCT01875731
- Testing
- BPS, Guideline
- Where
- Argentina
- Volunteers
- 66 people
- Sponsor
- Hospital General de Niños Pedro de Elizalde
Community Acquired Pneumonia, Complicated Skin and Soft Tissue Infection
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue…
- Trial name
- NCT04198571
- Testing
- Zinforo (ceftaroline fosamil)
- Where
- 26 sites in Brazil, Colombia and 5 more
- Volunteers
- 317 people
- Sponsor
- Pfizer
Pneumonia, Bacterial
A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
The purpose of this study is to test if intravenous sulopenem and an oral drug, PF-03709270 are safe and effective in patients that are hospitalized with community acquired pneumonia.
- Trial name
- NCT00797108
- Testing
- sulopenem and PF-03709270, Ceftriaxone and amoxicillin/clavulanate
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 35 people
- Sponsor
- Pfizer
Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia
CX-4945 in Viral Community Acquired Pneumonia
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated…
- Conditions
- Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia
- Trial name
- NCT06202521
- Testing
- CX-4945 (SARS-CoV-2 domain), CX-4945 (Influenza virus domain)
- Where
- 7 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Senhwa Biosciences, Inc.
Pneumonia
Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children
This is a multi-center, randomized, double-blind, placebo-controlled, superiority clinical trial will test the effectiveness of short (5-day) vs.standard (10-day) course therapy in children who are diagnosed with CAP and…
- Trial name
- NCT02891915
- Testing
- Amoxicillin, Amoxicillin-clavulanate, Cefdinir
- Where
- 9 sites in United States
- Volunteers
- 385 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia
Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Community Acquired Pneumonia
The aim of this study is to test if BPS (Bacterial Pneumonia Score) guided antibiotic use in children with non severe community acquired pneumonia (CAP) will reduce antibiotic use as compared to standard care practice (current…
- Trial name
- NCT01041209
- Testing
- Strategy based on BPS guided antibiotic use, Enforced Guidelines
- Where
- Argentina
- Volunteers
- 120 people
- Sponsor
- Hospital General de Niños Pedro de Elizalde
Community Acquired Pneumonia, Severe
Ticagrelor in Severe Community Acquired Pneumonia
The purpose of this study is to determine if the drug ticagrelor will be an effective treatment for patients with severe community acquired pneumonia.
- Trial name
- TCAP (NCT01998399)
- Testing
- Ticagrelor
- Where
- 26 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gordon Bernard
Community-Acquired Bacterial Pneumonia (CABP)
Phase II Study of Oral Nafithromycin in CABP
Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults
- Trial name
- NCT02903836
- Testing
- Nafithromycin 800 mg 3 days, Nafithromycin 800 mg 5 days, Moxifloxacin 400 mg
- Where
- 6 sites in United States
- Volunteers
- 231 people
- Sponsor
- Wockhardt
Community-acquired Pneumonia
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin (rhu-pGSN) Added to Standard of Care in Subjects…
- Trial name
- NCT03466073
- Testing
- Recombinant Human Plasma Gelsolin
- Where
- 8 sites in Australia, Georgia
- Volunteers
- 33 people
- Sponsor
- BioAegis Therapeutics Inc.
Community-acquired Pneumonia
OPEP Devices in Acute Inpatient Treatment of Pneumonia
This is a randomized-controlled prospective study to be conducted at Danbury Hospital and Norwalk Hospital to evaluate oscillatory positive expiratory pressure (OPEP) devices for "airway clearance" (helping to clear out phlegm or…
- Trial name
- OPEP (NCT04540510)
- Testing
- OPEP therapy, Standard care
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Danbury Hospital
Community Acquired Pneumonia
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate to severe community-acquired bacterial pneumonia.
- Trial name
- LEAP (NCT02559310)
- Testing
- lefamulin, Moxifloxacin, Linezolid
- Where
- 99 sites in United States, Argentina and 16 more
- Volunteers
- 551 people
- Sponsor
- Nabriva Therapeutics AG
Influenza, Pneumonia
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Current guidelines recommend early initiation of empiric antibiotic therapy to cover typical and atypical bacteria that may cause community-acquired pneumonia (CAP).
- Trial name
- RETOS (NCT01248715)
- Testing
- oseltamivir
- Where
- 5 sites in United States
- Volunteers
- 1,107 people
- Sponsor
- University of Louisville
Infections
Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
The purpose of this study is to determine whether ceftaroline is effective and safe for the treatment of patients with Community-acquired Bacterial Pneumonia (CABP) at risk for infection due to Methicillin-resistant…
- Trial name
- NCT01645735
- Testing
- Ceftaroline fosamil, Ceftriaxone plus vancomycin
- Where
- 31 sites in United States, Georgia and 6 more
- Volunteers
- 49 people
- Sponsor
- Forest Laboratories
Pneumonia, Bacterial
The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)
Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet been approved in Japan.
- Trial name
- NCT01189487
- Testing
- ampicillin sodium/sulbactam sodium
- Where
- 22 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Pfizer
Pneumonia
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)
The purpose of this study is to compare the efficacy of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).
- Trial name
- NCT00336505
- Testing
- Cethromycin, Clarithromycin
- Where
- 3 sites in United States
- Volunteers
- 584 people
- Sponsor
- Advanced Life Sciences, Inc.
Community-acquired Pneumonia, Bacterial Pneumonia
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
- Trial name
- NCT04779242
- Testing
- Omadacycline, Moxifloxacin
- Where
- 55 sites in Bulgaria, Croatia and 6 more
- Volunteers
- 670 people
- Sponsor
- Paratek Pharmaceuticals Inc